| 货号 | 3351/50 |
| 别名 | 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1- |
| 供应商 | Tocris |
| 生物活性 | Selective prostacyclin IP1 receptor agonist (Ki values are 260 and 2100 nM and for human and rat IP receptors, and >10 μM for EP1-4, DP, FP, and TP receptors). Prodrug for the active form of MRE 26. Ameliorates vascular endothelial dysfunction and increases femoral skin blood flow in rats. Orally available. |
| 运输条件 | Blue Ice |
| 存放说明 | -20℃ |
| 纯度 | >98 % |
| 计算分子量 | 496.62 |
| 分子式 | C26H32N4O4 |
| 可溶性/溶解性 | Soluble to 100 mM in DMSO |
| 参考文献 | Morrisonet al (2010) Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. J.Pharmacol.Exp.Ther. 335 249. PMID: 20660124. Kuwanoet al (2008) A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. J.Pharmacol.Exp.Ther. 326 691. PMID: 18552131. Kuwanoet al (2007) 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J.Pharmacol.Exp.Ther. 322 1181. PMID: 17545310. |